EANS-News: Epigenomics AG invites to Annual Press Conference and Analyst Meeting 2010

Not for distribution in the United States of America

--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

Company Information/Molecular diagnostics

Subtitle: Not for distribution in the United States of America

Berlin, Germany, and Seattle, WA, USA, March 25, 2010 (euro adhoc) -
Epigenomics AG (Frankfurt Prime Standard: ECX), invites media
representatives, analysts and shareholders to this year's Annual
Press Conference and Analyst Meeting on Monday, April 19, 2010 at
11:00 am (CET) at the premises of Villa Bonn in Frankfurt am Main,
Germany. The conference will be held in German language. On the same
day at 3:00 pm (CET)/9 am (EST) Epigenomics' management will host an
Analyst Conference Call conducted in English language.

Please note that the events were originally planned for March 31,
2010 but due to the company's ongoing capital increase and the legal
requirements and restrictions in external communication that go along
with this had to be rescheduled to April 19, 2010. Epigenomics would
like to thank you for your understanding and is looking forward to
welcoming you at these events.

The Annual Report will be released on March 31, 2010 as originally
planned.

Further Information

The annual report 2009 will be available at Epigenomics' website from
March 31, 2010 at:
www.epigenomics.com/en/investor_relations/Financial_Information/

Epigenomics will host the Annual Press Conference and Analyst Meeting
in German language on April 19, 2010 at 11 am CET at the premises of
the Villa Bonn - Frankfurter Gesellschaft für Handel Industrie und
Wirtschaft in Frankfurt am Main:

Villa Bonn
Frankfurter Gesellschaft für Handel Industrie und Wirtschaft
Siesmayerstrasse 12
60323 Frankfurt am Main
Room: Vortragsraum (OG)

An Analyst Conference Call will be hosted by Epigenomics' management
on the same day at 3 pm (CET)/9 am (EST). The conference call will be
conducted in English.

Dial-in number (within Germany.): +49 (0) 69 247 501 899
Dial-in number (outside Germany): +1 212 444 0297

Please dial-in at least 10 minutes prior to the start of the call.

To follow the presentation, we kindly ask all participants of the
call to download the slide set from the company website prior to the
call where it will be made available as a PDF file at 11 am CET (5 am
EST) on the same day via:
www.epigenomics.com/en/down_loads/corporate_material/

The conference call will be recorded and also made available on the
company website web as a audio file after the call. Please go to:
www.epigenomics.com/en/down_loads/corporate_material/

About Epigenomics

Epigenomics is a molecular diagnostics company with a focus on the
development of novel products for cancer. Using DNA methylation
biomarkers, Epigenomics' tests on the market and in development aim
at diagnosing cancer at an early stage before symptoms occur and
thereby may reduce mortality from this dreaded disease.

Epigenomics' product portfolio contains the CE-marked IVD test Epi
proColon, the world's first regulatory cleared molecular diagnostic
test for the detection of colorectal cancer in blood that is based on
the biomarker Septin9, and further proprietary DNA methylation
biomarkers and IVD products at various stages of development for
colorectal, lung and prostate cancer. For development and global
commercialization of IVD test products, Epigenomics pursues a dual
business strategy in which direct commercialization of proprietary
diagnostic test products is combined with non-exclusive licensing to
diagnostic industry players with broad customer access. Strategic
diagnostics industry partners include Abbott Molecular, Sysmex
Corporation, Quest Diagnostics Incorporated, and ARUP Laboratories,
Inc. for diagnostics test products and services, and QIAGEN N.V. for
sample preparation solutions and research products. The company is
headquartered in Berlin, Germany, and has a wholly owned subsidiary,
Epigenomics Inc., in Seattle, WA, U.S.A. For more information, please
visit Epigenomics' website at www.epigenomics.com.

Epigenomics legal disclaimers. This publication is not an offer of
any securities for sale or a solicitation of an offer to purchase any
securities. Any offer of shares will only be made by and on the basis
of a prospectus to be published. This document is not an offer of
securities for sale or a solicitation of an offer to purchase
securities in the United States. The shares of Epigenomics AG (the
"Shares") have not been registered under the U.S. Securities Act of
1933, as amended (the "Securities Act") and may not be offered or
sold in the United States unless registered under the Securities Act
or pursuant to an exemption from such registration. There will be no
public offering of the Shares in the United States and the Shares
will not be registered under the Securities Act. This document is
only being distributed to and is only directed at (i) persons who are
outside the United Kingdom or (ii) to investment professionals
falling within Article 19(5) of the Financial Services and Markets
Act 2000 (Financial Promotion) Order 2005 (the "Order") or (iii) high
net worth entities, and other persons to whom it may lawfully be
communicated, falling within Article 49(2)(a) to (d) of the Order
(all such persons together being referred to as "relevant persons").
The Shares are only available to, and any invitation, offer or
agreement to subscribe, purchase or otherwise acquire such securities
will be engaged in only with, relevant persons. Any person who is not
a relevant person should not act or rely on this document or any of
its contents.

This communication expressly or implicitly contains certain
forward-looking statements concerning Epigenomics AG and its
business. Such statements involve certain known and unknown risks,
uncertainties and other factors which could cause the actual results,
financial condition, performance or achievements of Epigenomics AG to
be materially different from any future results, performance or
achievements expressed or implied by such forward-looking statements.
Epigenomics AG is providing this communication as of this date and
does not undertake to update any forward-looking statements contained
herein as a result of new information, future events or otherwise.

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: Epigenomics AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Epigenomics AG

Dr. Achim Plum

Sen. VP Corporate Development

Tel: +49 30 24345 368

achim.plum@epigenomics.com

Branche: Biotechnology
ISIN: DE000A0BVT96
WKN: A0BVT9
Index: Prime All Share, Technology All Share
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Hamburg / free trade
Stuttgart / free trade
Düsseldorf / free trade
München / free trade